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Background
Last spring, headlines across the country spread the news 
that an outbreak of influenza-like illness was causing significant 
morbidity and mortality to the people of Mexico.  By April 2009, 
two children in the United States were diagnosed with a novel 
influenza A (H1N1) and this novel virus was found to be the 
cause of the respiratory outbreaks in Mexico. This new influenza 
virus spread quickly throughout the world.  On June 11, 2009, 
the World Health Organization (WHO) announced a world-
wide pandemic of uncontained community-level transmission 
of novel influenza H1N1 in numerous regions of the world.  
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 For most healthy people infected with influenza H1N1, the 
disease will be self-limited.  Several subpopulations including 
pregnant women have been identified at high risk for influenza 
H1N1 complications.  The designation of  pregnancy as a high 
risk condition was prompted by a very recent report by the Cen-
ters for Disease Control and Prevention (CDC) published in The 
Lancet 2009.
The Lancet report included all cases of infection with H1N1 
in pregnant women identified through the CDC between April 
15 and May 18, 2009 as well as the deaths associated with this 
virus during the first two months of the outbreak.  During the 
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first month of the outbreak, 34 cases of confirmed or probable 
cases of H1N1 in pregnant women were identified and reported 
to the CDC.  Eleven of these cases were admitted to the hospital. 
The admission rate for pregnant women infected with H1N1 
was almost four times higher than the admission rate found in 
the general population. The only difference in the clinical symp-
toms between pregnant women and the general population 
was a higher incidence of shortness of breath.  Also during the 
first month of the outbreak, the reported overall use of antiviral 
therapy increased, but only a quarter of these women started 
antiviral therapy in less than 48 hours of symptom onset.  By the 
end of the first two months of the outbreak, six pregnant women 
in the United States had died of influenza associated compli-
cations.  Four of the six deaths occurred in women who were 
in their third trimester of pregnancy.   All of these women de-
veloped pneumonia followed by respiratory distress syndrome 
requiring mechanical ventilation.   
Although the reliance on surveillance data and labora-
tory testing methods to determine which cases were reported 
do limit this study, the results strongly suggest that pregnant 
women infected with H1N1 are at increased risk as compared to 
the general population.  Similar adverse outcomes in pregnant 
women can be found in the historical observational reports from 
the prior influenza pandemics of 1918 and 1957.  During both of 
these pandemics, there was a surplus of influenza deaths among 
pregnant women with increased incidence of spontaneous abor-
tion and preterm labor.  In addition, multiple case reports as 
well as epidemiological reports show that pregnant women are 
also at increased risk for pregnancy complications during sea-
sonal influenza. Thus, prompting the recommendation that all 
pregnant women receive the seasonal influenza vaccine.
Clinical Presentation
Pregnant women infected with influenza H1N1 present with 
classic symptoms of acute respiratory illness. These symptoms 
include the typical cough, sore throat, rhinorrhea and fever. 
Other less typical presenting symptoms may be body aches, 
headache, fatigue, vomiting and diarrhea.  Many pregnant 
women will have a self-limited disease course, but for some, the 
disease progresses rapidly and may be complicated by pneumo-
nia, with subsequent respiratory distress syndrome requiring 
mechanical ventilation.  In less frequent cases, these complica-
tions have resulted in death.   The mortality rate among preg-
nant women is particularly high in those affected in the third 
trimester.  
Testing for influenza is not always necessary for a pregnant 
woman with fever and respiratory symptoms suspicious for flu; 
especially if she has had contact with others with confirmed 
H1N1. Rapid influenza testing is available but is poorly sensi-
tive.  Treatment decisions should not be based on a negative 
rapid test.  Unfortunately, novel influenza H1N1 testing remains 
unavailable at many locations, and when it is available it may 
take several days before results are available.  Antiviral therapy 
has been shown to be most effective early in the disease course; 
preferably within the first 48 hours of symptom onset.  Because 
of this, the CDC strongly recommends that antiviral therapy be-
gin as soon as possible without waiting for test results. If nec-
essary, the University of Iowa Hygienic Lab will perform PCR 
testing for influenza A and H1N1 confirmation. 
Antiviral Treatment
All pregnant women with clinical symptoms suspicious for 
H1N1 should have antiviral therapy begun as soon as possible 
without waiting for laboratory confirmation. Early antiviral 
therapy has been shown to decrease the severity of symptoms, 
shorten the illness, and prevent serious influenza complications. 
Pregnancy should not be considered a contraindication to start-
ing antiviral therapy. Benefits of these drugs in the treatment of 
H1N1 clearly outweigh the risk of antiviral therapy.  The neur-
aminindase inhibitor antiviral medication zanamivir (Relenza) 
and oseltamivir (Tamiflu) have both been shown to shorten the 
duration of influenza symptoms and the severity of the disease 
process.  Influenza H1N1 is resistant to the adamantane anti-
viral medications, amantadine (Symmetrel) and rimantadine 
(Flumadine).  
Oseltamivir is the preferred antiviral agent for treating in-
fluenza H1N1.  In contrast to zanamivir, oseltamivir is an oral 
medication and results in systemic absorption.  Zanamivir is 
given by inhalation therapy, thereby reducing systemic absorp-
tion.  Despite these differences, if oseltamivir is unavailable lo-
cally, treatment should be begun with zanamivir rather than to 
delay the onset of antiviral treatment.  The recommended dos-
age of oseltamivir is a 75 mg capsule twice per day for five days. 
Dosing directions for zanamivir is two 5 mg inhalations twice 
per day for 5 days. 
Chemoprophylaxis
When used to prevent seasonal influenza, antiviral drugs 
have been found to be about 70-90% effective against suscep-
tible viruses.  Pregnant women who have been in close contact 
with individuals who have symptoms of influenza-like illness 
should receive post-exposure chemoprophylaxis.  As one con-
siders which antiviral to prescribe for chemoprophylaxis, theo-
retically the antiviral of choice should probably be zanamivir 
because of its limited systemic absorption that is targeted spe-
cifically to the respiratory system.   However, because of the 
inhaled route of administration required for zanamivir admin-
istration, the side effect profile does include possible respiratory 
complications.  Therefore, women at known risk for respiratory 
problems should be prescribed oseltamivir rather than zanami-
vir.  The recommended duration of treatment for chemoprophy-
laxis for both antivirals is a total of 10 days following the last 
known exposure to influenza H1N1.  Chemoprophylaxis dose 
for zanamivir is two 5 mg inhalations once per day and the dose 
for oseltamivir is a 75 mg capsule once per day.  Of note, with 
seasonal influenza, the infectious period is considered begin-
ning one day prior to the onset of symptoms to up to 7 days 
after the infected person gets sick.  Therefore, if the contact with 
the infected person occurred more than 7 days after the onset of 
symptoms, chemoprophylaxis is most likely not needed.
Prevention
A vaccine for H1N1 is currently in development.  It is expect-
ed to be available for delivery to the public later this fall.  Un-
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til this occurs, the best methods of prevention are simple steps 
that reduce exposure to the virus.  The CDC general guidelines 
for prevention include the following steps: (1) Frequent hand 
washing, (2) Minimize contact with sick individuals, (3) Have ill 
persons stay home except to seek medical care, (4) Cover your 
mouth when you cough, (5) Avoid crowded settings in commu-
nities having outbreaks of influenza H1N1, (6) Use facemasks 
and respirators correctly, (7) Limit sharing of toys and anything 
else that has been in an infant’s mouth.  After exposure to the in-
fant’s mouth, wash these items thoroughly with soap and water.
Vaccine
Vaccination has been shown to be the most effective way to 
prevent influenza and its complications.  It is unlikely that the 
current seasonal influenza vaccines will prevent disease caused 
by novel influenza H1N1.  Studies have been done that have 
tested the seasonal influenza vaccine with cross-reactivity anti-
body to novel influenza H1N1.  Among adults aged 18-64 years, 
only 6% to 9% had titers that corresponded to a level that is con-
sidered high enough to protect them against influenza H1N1 af-
ter receiving seasonal vaccine.  In those adults aged > 60 years, 
33% achieved the necessary titer to protect them against novel 
influenza H1N1.  Specific vaccines are in the development pro-
cess, and are expected to be available by mid to late October 
2009.  It remains unclear whether the initial supply of vaccine 
will be enough to meet population demand.  Another factor that 
may affect initial supply is the number of vaccine doses needed 
to provide adequate protection.  It has been established that in 
children < 9 years, two doses of seasonal influenza vaccine are 
required to induce immunity because young children do not 
have preexisting antibodies.  It follows then that an additional 
dose of novel influenza H1N1 may also be required in children 
and young adults in order to provide a sufficient level of im-
munity.  Studies are currently ongoing to determine which age 
groups may require the second dose of vaccine for adequate 
protection.  An additional dose required per person may cer-
tainly affect whether there will be enough initial supply to meet 
demand.  Because of these factors, the Centers for Disease Con-
trol and Prevention have identified five specific groups that are 
considered to be at high risk for influenza H1N1 and its com-
plications.  These groups will be targeted for early vaccination.
Recommendations for Vaccine Usage
The Advisory Committee on Immunization Practices (ACIP) 
recommends that early vaccination should focus on five specific 
high risk groups. These groups include: (1) pregnant women, 
(2) persons who live with or provide care for infants aged < 6 
months, (3) health care workers and emergency medical servic-
es personnel, (4) persons aged 6 months - 24 years, (5) persons 
aged 25 - 64 years who have medical conditions that put them 
at higher risk for influenza complications.  In the United States, 
these five groups contain an estimated 159 million people.
If the initial supply fails to meet population demand in spe-
cific geographic areas, the Advisory Committee has developed 
a plan to target a subset of the five initial target groups.  These 
subset groups are comprised of: (1) pregnant women, (2) per-
sons who live with or provide care for infants < 6 months, (3) 
health care and emergency medical services personnel, (4) chil-
dren aged 6 months – 4 years, (5) children and adolescents aged 
5-18 years who have medical conditions that put them at higher 
risk for influenza related complications.  It is estimated that 
these subset groups would comprise approximately 42 million 
people in the United States.  As the initial supply increases, deci-
sions to expand vaccination outside of the target groups should 
be made based on the judgment of state and local health officials 
to best meet the needs of a specific region.
Infant Considerations
Infants are at high risk for influenza-related illness.  It is well 
known that breastfed infants are less susceptible to respiratory 
illness when compared to bottle fed infants. Mothers should be 
highly encouraged to breastfeed their infants.  The CDC addi-
tionally recommends that unnecessary formula supplementa-
tion be eliminated so that the infant receives as much maternal 
antibody as is possible.  Ideally, only healthy adults should care 
for infants.  This includes infant feeding.  The risk for transmis-
sion of influenza H1N1 through breast milk remains unknown. 
However, reports of seasonal flu viremia have shown that the 
risk of virus crossing into breast milk is rare.  Theoretically, this 
should also be true for influenza H1N1.  Both oseltamivir and 
zanamivir are considered to be compatible with breastfeeding. 
Women infected with H1N1 should be encouraged to express 
their milk so that healthy adults can bottle feed the infants with 
antibody rich breast milk.  
Summary of Current Recommendations
1.  Pregnant women are at high risk for influenza related com-
plications.
2.   Testing for influenza is not always necessary for a pregnant 
woman with fever and respiratory symptoms suspicious 
for flu; especially if she has had contact with others with 
confirmed H1N1.  Treatment decisions should not be based 
on a negative rapid test.  Testing should be considered in 
hospitalized patients or if the diagnosis is uncertain.  Rapid 
influenza testing is available but is poorly sensitive.  If nec-
essary, the PCR testing for H1N1 is available thru the Uni-
versity of Iowa Hygienic Lab (please see website below). 
3. Begin treatment with empiric antiviral therapy as soon as 
possible and preferably within the first 48 hours of symp-
tom onset.  For women who have had symptoms beyond 
two days there is evidence that antiviral therapy may still 
be beneficial.  
4.  Oseltamavir is considered the first line agent for the treat-
ment of H1N1 influenza. This drug is administered orally 
and has improved systemic absorption when compared to 
zanamivir.  Side effects are fairly minimal with the most 
common reported being nausea and vomiting. Treatment 
dose is 75 mg PO BID for 5 days.
5.  Zanamivir is also acceptable for the treatment of 2009 
H1N1.  The route of administration is inhalation and has 
decreased systemic absorption when compared to oselta-
mivir.  Side effects include bronchospasm and may lead to 
respiratory complication in persons with underlying respi-
ratory disease.
6.  Pregnant women who have been in close contact with in-
dividuals who have symptoms of influenza-like illness 
should receive post-exposure chemoprophylaxis.
7.   For chemoprophylaxis in pregnant women, a preferred 
antiviral has not been determined.  Zanamivir is generally 
not recommended in persons with underlying lung disease 
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such as asthma and chronic obstructive pulmonary disease. 
Chemoprohylaxis with Oseltamavir is 75 mg PO once a day 
for 10 days is recommended.
8.   2009 H1N1 Vaccine should be available by mid to late Octo-
ber.  All pregnant women should be highly encouraged to 
get the H1N1 vaccine as well as the seasonal vaccine.
9.   Preliminary data suggests that older children and adults 
will only require one dose of H1N1 vaccine to acquire im-
munity
10.  Simultaneous administration of inactivated vaccines 
against seasonal and 2009 H1N1 is acceptable if different 
anatomic sites are used.
11.  Using data from seasonal influenza viremia, the risk of 
H1N1 virus crossing into breast milk is considered rare. 
The CDC highly encourages breastfeeding from both 
healthy and infected mothers so that the infant receives as 
much maternal antibody as is possible.  
12.   Only healthy adults should be caring for infants.  It is 
recommended that infected mothers should express their 
breastmilk and allow a healthy adult to bottle feed the in-
fant the expressed breastmilk. 
13.   Prevention is the key to controlling the 2009 H1N1 influ-
enza pandemic.  The Centers for Disease and Prevention 
Guidelines are as follows:
a.   Wash hands frequently with soap and water or use  
alcohol-based hand cleaner.
b.   Cover your mouth and nose with a tissue when 
coughing or sneezing.
c.    Avoid touching your eyes, nose and mouth.
d.  People who are sick with an influenza-like illness 
should stay home and avoid travel for at least 24 
hours after fever is gone.
e.    Avoid close contact (within about 6 feet) with per-
sons with influenza like symptoms.
f.   The effectiveness of respirators and facemasks in pre-
venting transmission of influenza virus is not known. 
Use of a facemask or respirator is of most  bene-
fit if used consistently when exposed to an ill person.
g.   Respirators (such as N95 or high filtering device) re-
quire fitting, medical clearance.  Facemasks may be 
considered as an alternative to respirators.
h.   Use of respirators of facemasks generally are not rec-
ommended for workers in non-healthcare settings 
for general work activities. 
i.    Ill persons should be placed in well ventilated areas 
when possible and placed at least 6 feet away from 
other people.
14.  KEY - Information regarding 2009 Influenza H1N1 is evolv-
ing rapidly.  Recommendations are frequently updated as 
more information is learned regarding 2009 H1N1.  Please 
refer to the websites below to stay updated regarding the 
latest information:
—Kathy Kyser, MD  —Janet Andrews, MD 
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Websites
Federal Sites:
- Agency for Healthcare Research and Quality: Tools and  
Resources for Influenza Preparedness    
http://www.ahrq.gov/prep/swineflu.htm
- Centers for Disease Control & Prevention (CDC):  H1N1 Flu 
(Swine Flu) http://www.cdc.gov/h1n1flu
- National Library of Medicine (NLM) Enviro-Health Links:  
2009 H1N1 Flu  
http://sis.nlm.nih.gov/enviro/swineflu.html
State Sites:
- CDC Public Health Resources:  State Health Departments 
(MMWR):  
http://www.cdc.gov/mmwr/international/relres.html
Select state to go to that state’s general health department  
website.
- Iowa Department of Public Health www.idph.state.ia.us/
Professional Organization:
- American College of Obstetricians and Gynecologists (ACOG) 
www.acog.org
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